Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double ‐blind, randomized, placebo‐controlled clinical trial

ConclusionIntravenous immunoglobulin therapy does not significantly improve cardiac systolic function or functional capacity beyond standard medical therapy in patients with idiopathic chronic DCM and cardiac B19V persistence.Clinical Trial Registration:ClinicalTrials.gov ID NCT00892112.

Source: European Journal of Heart Failure - January 7, 2021 Category: Cardiology Authors: Mark R. Hazebroek, Michiel T.H.M. Henkens, Anne G. Raafs, Job A.J. Verdonschot, Jort J. Merken, Robert M. Dennert, Casper Eurlings, Myrurgia A. Abdul Hamid, Petra F.G. Wolffs, Bjorn Winkens, Hans ‐Peter Brunner‐La Rocca, Christian Knacksted Tags: Research Article Source Type: research